The biopharmaceutical industry descended on our hometown in San Diego this week to participate in the BIO International Convention #BIO2024. Once again, Travere sponsored a breakfast for patient advocates attending the convention, where our president and CEO Eric Dube addressed a full room. Sika Dunyoh, senior director of patient advocacy, moderated a panel on patient-focused drug development featuring Danaé Bartke, co-founder of HCU Network America. #StandUpForScience #InRareForLife #TravereTherapeutics #PatientAdvocacy
Travere Therapeutics’ Post
More Relevant Posts
-
In our latest video, we explore the partnership between pharmaceutical companies and patient advocacy groups. Discover how this collaboration amplifies patient voices and accelerates medical research. Click the link to check out our video! #PatientAdvocacy https://bit.ly/41RwEZf
To view or add a comment, sign in
-
-
We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy
To view or add a comment, sign in
-
We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024
To view or add a comment, sign in
-
-
We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024
To view or add a comment, sign in
-
-
We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024
To view or add a comment, sign in
-
-
We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024
To view or add a comment, sign in
-
-
The PALADIN Skills and Training Workstream has developed training materials to help Patient Advocacy Groups (PAGs) and the industry understand each other better and create effective working relationships. Visit the link below to learn about the 5 key things patient advocacy groups should know about biopharmaceutical companies: https://lnkd.in/eAgj5Vu2
To view or add a comment, sign in
-
Mega proud to be part of this wonderful initiative. If you are involved in a partnership between biopharmaceutical companies and patient organisations, there is still time to register to take part via the link below!! Partnerships can be in any of the following: 💗Communications 📢 Advocacy 🌐Market Access 🔬Clinical trials 🧪R&D #patientadvocacy #marketaccess #healthcarecommunications
The end is fast approaching! Just 1 day to go until registrations close for the Patient Partnership Index 2023. If you would like to showcase your involvement in a partnership between biopharmaceutical companies and patient organisations across communications, advocacy, market access, clinical trials, or R&D, register now to submit an entry. Entries can be led by either partner and will be judged against a bespoke metric developed in partnership with industry and patient organisations to award Gold, Silver or Finalist standards. Entries to the Index close at 23:55 on Friday 26th April, so register now to receive an entry form, and ensure your partnerships get the recognition they deserve. The registration form, alongside FAQs and insights from last year’s Index, can be found via the link in comments. If you have any questions or require further support to get your entry (or entries) in by Friday, please reach out to the PPI team at [email protected]. #clinicaltrials #marketaccess #researchanddevelopment #patientadvocacy #healthcarecommunications
To view or add a comment, sign in
-
Are you attending the World Orphan Drug Congress April 23 - 25, 2024 in Boston? If you need reasons to attend, here are 3 great reasons: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I’ll be there!! If you are attending, leave me a comment - I am looking to meet people! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma
To view or add a comment, sign in
-
-
Program Design & Development | Patient Advocacy | Patient-Clinician Communication | Public Communication
If you are attending #DIAglobal, be sure to check out this panel!
We are thrilled to announce that we will be speaking at the #DIAGlobal conference in San Diego, CA, on June 18th. Join us to learn about PALADIN’s mission to transform the pace of medicines development through collaboration between patient advocacy groups and pharmaceutical companies. We will also provide an update on the PALADIN Consortium. Victoria DiBiaso Ken Getz Hollie Schmidt #DIAGlobal #DIAConference2024
To view or add a comment, sign in
-